menu search

TEVA / Teva Pharmaceutical announces new growth strategy built on biosimilars, innovation

Teva Pharmaceutical announces new growth strategy built on biosimilars, innovation
Teva Pharmaceutical Industries on Thursday launched a new “pivot to growth” strategy, based on existing growth drivers like Austedo and Ajovy as well as generics, further innovation, and focused capital allocation. The company expects annual sales of more than $2.5 billion by 2027 for Austedo, which treats involuntary movements associated with Huntington's disease. Read More
Posted: May 18 2023, 09:05
Author Name: Market Watch
Views: 092144

TEVA News  

Drugmaker Teva does not see big impact on business from Israel-Hamas war

By Reuters
October 10, 2023

Drugmaker Teva does not see big impact on business from Israel-Hamas war

Israel's war with Hamas is not expected to have much impact on Teva Pharmaceutical Industries' business performance, the company said on Tuesday. more_horizontal

TEVA: A Pharmaceutical Stock to Watch Right Now

By See It Market
September 12, 2023

TEVA: A Pharmaceutical Stock to Watch Right Now

Every week, I am invited on Business First AM with Angela Miles to discuss the market and give a stock pick. This week, I covered TEVA, a stock I have more_horizontal

Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

By Seeking Alpha
September 11, 2023

Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript)

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023 8:40 AM ET Co more_horizontal

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

By Seeking Alpha
August 26, 2023

The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider

On August 2, Teva Pharmaceutical published its financial report for the second quarter of 2023, which showed an improvement in its financial position. more_horizontal

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

By Zacks Investment Research
August 23, 2023

TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 an more_horizontal

TEVA to Pay $250 Million to Settle Price-Fixing Charges

By Zacks Investment Research
August 22, 2023

TEVA to Pay $250 Million to Settle Price-Fixing Charges

TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 an more_horizontal

Teva Pharma lands US$225 million fine for price-fixing

By Proactive Investors
August 22, 2023

Teva Pharma lands US$225 million fine for price-fixing

Generic drug maker Teva Pharmaceuticals is to pay US $225 million in fines after admitting price-fixing on a range of drugs in the US. Teva and anothe more_horizontal

Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges

By CNN Business
August 21, 2023

Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges

Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholestoral to settle price-fixing charges f more_horizontal


Search within

Pages Search Results: